- Home
- ALX vs APLT Comparison
ALX vs APLT Comparison
Compare ALX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- APLT
- Stock Information
- Founded
- ALX 1928
- APLT 2016
- Country
- ALX United States
- APLT United States
- Employees
- ALX N/A
- APLT N/A
- Industry
- ALX Real Estate Investment Trusts
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- APLT Health Care
- Exchange
- ALX Nasdaq
- APLT Nasdaq
- Market Cap
- ALX 1.2B
- APLT 971.6M
- IPO Year
- ALX N/A
- APLT 2019
- Fundamental
- Price
- ALX $226.70
- APLT $8.92
- Analyst Decision
- ALX Sell
- APLT Strong Buy
- Analyst Count
- ALX 1
- APLT 5
- Target Price
- ALX $125.00
- APLT $12.50
- AVG Volume (30 Days)
- ALX 12.1K
- APLT 1.7M
- Earning Date
- ALX 11-04-2024
- APLT 11-07-2024
- Dividend Yield
- ALX 7.94%
- APLT N/A
- EPS Growth
- ALX N/A
- APLT N/A
- EPS
- ALX 10.04
- APLT N/A
- Revenue
- ALX $233,137,000.00
- APLT N/A
- Revenue This Year
- ALX N/A
- APLT N/A
- Revenue Next Year
- ALX N/A
- APLT $3,349.45
- P/E Ratio
- ALX $22.83
- APLT N/A
- Revenue Growth
- ALX 9.25
- APLT N/A
- 52 Week Low
- ALX $179.25
- APLT $1.79
- 52 Week High
- ALX $251.63
- APLT $9.39
- Technical
- Relative Strength Index (RSI)
- ALX 42.14
- APLT 64.25
- Support Level
- ALX $227.65
- APLT $8.43
- Resistance Level
- ALX $236.90
- APLT $9.25
- Average True Range (ATR)
- ALX 3.98
- APLT 0.54
- MACD
- ALX -0.52
- APLT -0.04
- Stochastic Oscillator
- ALX 11.27
- APLT 82.76
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.